Literature DB >> 20500661

Distinct host-related dendritic cell responses during the early stage of Plasmodium yoelii infection in susceptible and resistant mice.

W Zheng1, Q-H Wang, Y-J Liu, J Liu, H Feng, J-J Wu, Y-M Cao.   

Abstract

The diverse outcomes of experimental murine infection with Plasmodium parasites, ranging from spontaneous cure to death, depend largely on the establishment of an effective Th1 immune response during the early stages of infection. However, the molecular and cellular factors responsible for the induction and regulation of this response are poorly understood. As immunity is initiated by dendritic cells (DCs), we compared their phenotype and function during the early stages of infection with Plasmodium yoelii 17XL (P.y 17XL) strain in susceptible (BALB/c) and resistant (DBA/2) mice. Resistant DBA/2 mice developed a greater number of myeloid (CD11c(+)CD11b(+)) and mature DCs, which were fully functional and capable of secreting IL-12p40. In contrast, susceptible BALB/c mice produced more plasmacytoid (CD11c(+)CD45R/B220(+)) and less mature DCs, resulting in high levels of IL-10 and TGF-beta1. In addition, an in vitro experiment confirmed that splenic DCs from the two strains of mice differ in their ability to prime CD4(+)T cells in response to P.y 17XL stimulation. These findings indicate that the subset, the phenotype and the type of inflammatory and anti-inflammatory signals of splenic DCs are critical factors responsible for the discrepancy in the ability to induce or regulate Th1 immune responses in different hosts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20500661     DOI: 10.1111/j.1365-3024.2009.01190.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  7 in total

Review 1.  Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens.

Authors:  Joshua C Cyktor; Joanne Turner
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

2.  Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.

Authors:  Sophie Schussek; Angela Trieu; Simon H Apte; John Sidney; Alessandro Sette; Denise L Doolan
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

3.  Interleukin-10 (IL-10) polymorphisms are associated with IL-10 production and clinical malaria in young children.

Authors:  Guicheng Zhang; Maria Nelia Manaca; Michelle McNamara-Smith; Alfredo Mayor; Augusto Nhabomba; Tamara Katherine Berthoud; Siew-Kim Khoo; Selma Wiertsema; Ruth Aguilar; Arnoldo Barbosa; Llorenç Quintó; Pierre Candelaria; En Nee Schultz; Catherine M Hayden; Jack Goldblatt; Caterina Guinovart; Pedro L Alonso; Peter N Lesouëf; Carlota Dobaño
Journal:  Infect Immun       Date:  2012-05-07       Impact factor: 3.441

4.  Host Resistance to Plasmodium-Induced Acute Immune Pathology Is Regulated by Interleukin-10 Receptor Signaling.

Authors:  Carla Claser; J Brian De Souza; Samuel G Thorburn; Georges Emile Grau; Eleanor M Riley; Laurent Rénia; Julius C R Hafalla
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

5.  Multivariable analysis of host amino acids in plasma and liver during infection of malaria parasite Plasmodium yoelii.

Authors:  Erisha Saiki; Kenji Nagao; Hiroka Aonuma; Shinya Fukumoto; Xuenan Xuan; Makoto Bannai; Hirotaka Kanuka
Journal:  Malar J       Date:  2013-01-16       Impact factor: 2.979

6.  Age-related CD4(+)CD25(+)Foxp3(+) regulatory T-cell responses during Plasmodium berghei ANKA infection in mice susceptible or resistant to cerebral malaria.

Authors:  Ying Shan; Jun Liu; Yan-Yan Pan; Yong-Jun Jiang; Hong Shang; Ya-Ming Cao
Journal:  Korean J Parasitol       Date:  2013-06-30       Impact factor: 1.341

7.  Pre-existing Schistosoma japonicum infection alters the immune response to Plasmodium berghei infection in C57BL/6 mice.

Authors:  Mei-lian Wang; Ya-ming Cao; En-jie Luo; Ying Zhang; Ya-jun Guo
Journal:  Malar J       Date:  2013-09-14       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.